Santen Pharmaceutical Co Ltd (4536.T) stock: key figures, P/E, revenue and dividend
Health Care · Japan · ISIN JP3336000009
Santen Pharmaceutical Co Ltd financials
| Fiscal year | 2025 | 2026 |
|---|---|---|
| Revenue | 300.00 bn JPY | 291.62 bn JPY |
| Gross profit | 163.21 bn JPY | 160.97 bn JPY |
| EBIT | 56.23 bn JPY | 45.57 bn JPY |
| Net income | 36.26 bn JPY | 37.37 bn JPY |
| Diluted EPS – continuing operations | 112.02 JPY | 115.84 JPY |
Full history since 1994, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Santen Pharmaceutical Co Ltd
Santen Pharmaceutical Co., Ltd. engages in the research and development, production, and marketing of pharmaceuticals and medical devices in Japan, China, Asia, Europe, the Middle East, Africa, and internationally. The company operates through Medical drugs, Over-the-counter drugs, Medical equipment, and others segments. It products include Taflupro/Timolol maleate, a combination drug of a prostaglandin Fa derivative and a beta-blocker for the treatment of glaucoma and ocular hypertension area; omidenepagisopropyl, an EP2 receptor agonist that is in phase II clinical trial for the treatment of glaucoma and ocular hypertension area; cepetaprost, an FP/EP3 receptor agonist that is in phase II clinical trial for the treatment of glaucoma and ocular hypertension area; latanoprost, a prostaglandin Fa derivative emulsified eye drops; netalusdil mesylate, a ROCK/NET inhibitor; Netalus, a combination drug of a ROCK inhibitor and a prostaglandin Fa derivative; netalusdyl mesialate/latanoprost, a combination drug of a ROCK inhibitor and a prostaglandin Fa derivative that is in phase I clinical trial for the treatment of glaucoma and ocular hypertension area. The company also provides cyclosporine, which is used for vernal catarrhal infections; olodaterol hydrochloride, used for dry eye that is in late-stage Phase 11 trial for the treatment of Keroconjunctival disease; olodaterol hydrochloride, used for allergic conjunctivitis that is in the Phase I/Early Phase II trial for the treatment of Keroconjunctival disease; epinastine hydrochloride, an eyelid cream formulation for allergic conjunctivitis; epinastine, a high-dose eye drop formulation for allergic conjunctivitis; nintedanib, a drug targeting pterygium that is in late-stage Phase II trial for the treatment of Keroconjunctival disease; and eflimrufuspalfa, which is used for diabetic macular edema. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Kita, Japan.
More stocks
- Fastly, Inc. (FSLY)
- AVIS BUDGET GROUP, INC. (CAR)
- SMG Swiss Marketplace Group Holding AG (SMG.SW)
- Andon Health Co Ltd (002432.SZ)
- Transcend Information Inc (2451.TW)
- ERG SpA (ERG.MI)
- INDEPENDENCE REALTY TRUST, INC. (IRT)
- Nikon Corp (7731.T)
- Ferrotec (Anhui) Technology Development Co. Ltd. A (301297.SZ)
- Koei Tecmo Holdings Co Ltd (3635.T)
- NICOLET BANKSHARES INC (NIC)
- Liquidia Corp (LQDA)
Not investment advice. All data without warranty, price as of 23.10.2026. Details in the risk notice.